ARS Pharmaceuticals (SPRY) Long-Term Investments (2021 - 2022)

ARS Pharmaceuticals (SPRY) reported Long-Term Investments of $24.2 million for Q2 2022, down 44.93% sequentially from $44.0 million in Q1 2022.

ARS Pharmaceuticals (SPRY) Long-Term Investments (2021 - 2022) Analysis & Trends

ARS Pharmaceuticals (SPRY) has 2 years of Long-Term Investments data on file, last reported at $24.2 million in Q2 2022.

For the quarter ending Q2 2022, Long-Term Investments changed N/A year-over-year to $24.2 million; the trailing twelve-month figure through Jun 2022 stood at $24.2 million (changed N/A YoY), and the FY2021 full-year result was $64.8 million, changed N/A from the prior year.
Long-Term Investments slipped to $24.2 million in Q2 2022, from $44.0 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $64.8 million in Q4 2021 to a low of $24.2 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	505,194.89
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	ARS Pharmaceuticals	595.78 Mn	394.81 Mn	-	-

Download Data